Among six AML cell lines (3 with mutated, 3 with wildtype TP53) treated with DAC and ATRA, single-agent activity upon cell growth inhibition was variable (with notable ATRA sensitivity of the three cell lines with MLL rearrangements), without antagonistic effects (Fig. 1A, B). The gene discussed is KMT2A; the disease is acute myeloid leukemia.